This page should automatically redirect. If nothing is happening please use the continue link below.
(Continue)
Targeting CD19+ B-Cells: Bridging pathophysiology and clinical evidence in Generalised Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder Sponsored Content by: Amgen